ROCKVILLE, MD, SEATTLE, WA (USA) June 23, 2009
-MEDIFACTS INTERNATIONAL, INC. a leading global cardiovascular core lab announced today the acquisition of the Clinical Trials Services division of Spacelabs Healthcare, Inc. (“CTS”). Financial terms of the transaction were not disclosed.
The combination of Medifacts International and CTS, a global provider of integrated, centralized cardiovascular safety and diagnostic services to the pharmaceutical and biotechnology industries, brings together Medifacts’ industry-leading scientific and regulatory expertise, global logistics and support infrastructure with CTS’ demonstrated commitment to technology, service excellence and client-focused solutions.
Michael Woehler, PhD, President and CEO of Medifacts said: “This combination brings together two highly motivated teams that share a passion for delivering the highest quality service, and creates the broadest product offering of cardiac safety and efficacy services for Phase I through IV clinical trials to pharmaceutical, biotech and medical device manufacturers worldwide. We are delighted to welcome the CTS team into the Medifacts organization today.”
Dr Woehler added, “The combination enhances our existing client relationships and creates an even stronger partner for new and existing clients alike. Medifacts is committed to assisting companies navigate the complex regulatory and scientific requirements throughout the drug development clinical trial process in a fast and cost efficient manner. Our acquisition of the CTS business today is a further demonstration of that commitment.”
John Carpentier, General Manager of CTS commented, “Through the combination with Medifacts, we will be able to provide existing and future clients with a wide array of ECG, Holter, and Blood Pressure technologies supported by the industry's most experienced technologists and scientific experts. I am excited to be joining the Medifacts group and look forward to serving all of our clients as a part of this world class team.”
About MEDIFACTS
Driven by best-in-class Science, Technology, and Service Quality, Medifacts International has become a global leader providing ECG, Holter, Ambulatory Blood Pressure Monitoring, Spirometry, Glucometry, Pulse Wave Analysis and related services to pharmaceutical, biotech and medical device companies.
Medifacts International’s scientific expertise, proprietary WebHeart® technology, global presence and recognized quality leadership has established Medifacts as one of the top 3 providers worldwide in comprehensive cardiac safety and efficacy services
About SPACELABS HEALTHCARE, INC.
Spacelabs Healthcare, Inc.
is an international developer, manufacturer and distributor of medical equipment and services including patient monitoring solutions, anesthesia delivery and ventilation systems, diagnostic cardiology solutions and supplies and accessories selling to hospitals, clinics and physicians offices. Additionally, the company provides ECG laboratory services to pharmaceutical companies undertaking clinical trials, whereby patient ECG data is recorded, analyzed, tabulated and interpreted.
The company has established brand names in both medical devices and medical services such as "Spacelabs," "Blease," Del Mar Reynolds and "Dolphin." It employs approximately 1,500 personnel in its offices located in the United States, UK, Canada, France, Germany, Finland, India and Singapore.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.